FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Bespoke Gene Therapy Portfolio has 8 Diseases

The Bespoke Gene Therapy Consortium, of which FDA is a member, chooses eight rare diseases for a clinical trial portfolio intended to speed the develo...

latest-news-card-1
Human Drugs

Let Compounders Help with Drug Shortages: Op-Ed

The Alliance for Pharmacy Compounding calls for changes to federal law to allow compounding pharmacies to help address temporary drug shortages under ...

latest-news-card-1
Human Drugs

Did Recarbrio Approval Break FDA Rules?

A BMJ investigation questions how FDA approved Mercks antibiotic Recarbrio in 2019 since it did not appear to meet agency requirements for substantial...

latest-news-card-1
Biologics

Split Vote on Sarepta Gene Therapy

FDAs Cellular, Tissue, and Gene Therapies Advisory Committee gives a split vote of 8 to 6 to recommend approval of a Sarepta BLA seeking accelerated a...

latest-news-card-1
Federal Register

Regulatory Review Period for Cablivi

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Sanofis Cablivi (caplacizumab-yhdp).

latest-news-card-1
Federal Register

Allergan Skin Smoother Approved by FDA

FDA approves Allergan Aesthetics Skinvive by Juvderm and its use to improve skin smoothness of the cheeks in adults.

latest-news-card-1
Human Drugs

Pedicle Screw Bone Awl Cleared

FDA clears a Waypoint Orthopedics 510(k) for the Waypoint GPS, a smart bone awl for use during pedicle screw pilot hole drilling.

latest-news-card-1
Human Drugs

Guide on Reporting Animal Drug Shortages

FDA releases a final guidance entitled Reporting and Mitigating Animal Drug Shortages that covers voluntary submissions from sponsors so agency can he...

latest-news-card-1
Human Drugs

Globus Gets HDE for Scoliosis Corrector

FDA grants Globus Medical a humanitarian device exemption to allow the marketing of the Reflect Scoliosis Correction System.

latest-news-card-1
Federal Register

Onpattros Regulatory Review Period Determined

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Alnylam Pharmaceuticals Onpattro (patisiran).